Symbols / XGN $3.17 -2.46%
XGN Chart
About
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 71.84M |
| Enterprise Value | 69.12M | Income | -19.04M | Sales | 63.60M |
| Book/sh | 0.81 | Cash/sh | 1.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | 209 | IPO | — |
| P/E | — | Forward P/E | -10.34 | PEG | — |
| P/S | 1.13 | P/B | 3.93 | P/C | — |
| EV/EBITDA | -6.55 | EV/Sales | 1.09 | Quick Ratio | 3.63 |
| Current Ratio | 4.08 | Debt/Eq | 155.29 | LT Debt/Eq | — |
| EPS (ttm) | -0.93 | EPS next Y | -0.31 | EPS Growth | — |
| Revenue Growth | 37.90% | Earnings | 2026-05-04 | ROA | -14.66% |
| ROE | -122.81% | ROIC | — | Gross Margin | 59.86% |
| Oper. Margin | -17.98% | Profit Margin | -29.94% | Shs Outstand | 22.66M |
| Shs Float | 14.53M | Short Float | 4.76% | Short Ratio | 1.30 |
| Short Interest | — | 52W High | 12.23 | 52W Low | 2.91 |
| Beta | 1.91 | Avg Volume | 487.21K | Volume | 11.02K |
| Target Price | $9.83 | Recom | Strong_buy | Prev Close | $3.25 |
| Price | $3.17 | Change | -2.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.83
Mean price target
2. Current target
$3.17
Latest analyst target
3. DCF / Fair value
$-5.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.17
Low
$8.00
High
$12.00
Mean
$9.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Keybanc | Overweight → Overweight | $10 |
| 2026-03-10 | main | BTIG | Buy → Buy | $9 |
| 2026-02-24 | main | TD Cowen | Buy → Buy | $10 |
| 2026-02-17 | main | BTIG | Buy → Buy | $10 |
| 2026-01-30 | reit | B. Riley Securities | Buy → Buy | $8 |
| 2025-11-10 | main | BTIG | Buy → Buy | $15 |
| 2025-11-05 | reit | B. Riley Securities | Buy → Buy | $18 |
| 2025-10-27 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2025-10-22 | main | BTIG | Buy → Buy | $13 |
| 2025-10-14 | main | Keybanc | Overweight → Overweight | $15 |
| 2025-09-11 | init | B. Riley Securities | — → Buy | $15 |
| 2025-07-30 | main | Canaccord Genuity | Buy → Buy | $11 |
| 2025-07-30 | up | Keybanc | Sector Weight → Overweight | $12 |
| 2025-07-23 | init | Craig-Hallum | — → Buy | $12 |
| 2025-05-15 | main | Cantor Fitzgerald | Overweight → Overweight | $7 |
| 2025-05-13 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2025-01-13 | reit | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2025-01-03 | main | Canaccord Genuity | Buy → Buy | $7 |
| 2024-05-14 | main | Cantor Fitzgerald | Overweight → Overweight | $7 |
| 2023-09-26 | reit | Cantor Fitzgerald | Overweight → Overweight | $6 |
News
RSS: Latest XGN news- KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Wed, 11 Mar 2026 13
- EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative ue, 10 Mar 2026 12
- Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus ue, 10 Mar 2026 21
- Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance ue, 10 Mar 2026 13
- William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka ue, 10 Mar 2026 22
- Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat ue, 10 Mar 2026 20
- Exagen Inc. (XGN) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget Mon, 09 Mar 2026 23
- Exagen Earnings Report: Q4 Overview - Benzinga ue, 10 Mar 2026 12
- Autoimmune test firm Exagen lines up March investor meetings - Stock Titan ue, 03 Mar 2026 14
- Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com Wed, 11 Mar 2026 11
- Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill ue, 10 Mar 2026 13
- $XGN stock is down 14% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 19
- XGN: B. Riley Securities Lowers Price Target, Maintains Buy Rati - GuruFocus Mon, 09 Mar 2026 06
- Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat ue, 10 Mar 2026 12
- BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com South Africa ue, 10 Mar 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2535 | 7800 | — | Stock Award(Grant) at price 3.08 per share. | ABALLI JOHN | Chief Executive Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 15698 | 56827 | — | Sale at price 3.62 per share. | ABALLI JOHN | Chief Executive Officer | — | 2026-03-03 00:00:00 | D |
| 2 | 1584 | 5718 | — | Sale at price 3.61 per share. | BLACK JEFFREY G | Chief Financial Officer | — | 2026-02-24 00:00:00 | D |
| 3 | 11430 | 41262 | — | Sale at price 3.61 per share. | ABALLI JOHN | Chief Executive Officer | — | 2026-02-24 00:00:00 | D |
| 4 | 31787 | 375598 | — | Sale at price 11.82 per share. | ABALLI JOHN | Chief Executive Officer | — | 2025-10-16 00:00:00 | D |
| 5 | 20466 | 200362 | — | Sale at price 9.79 per share. | BLACK JEFFREY G | Chief Financial Officer | — | 2025-09-02 00:00:00 | D |
| 6 | 350000 | 1155000 | — | Sale at price 3.30 per share. | NMSIC CO-INVESTMENT FUND, L.P | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-25 00:00:00 | I |
| 7 | 8621 | 29829 | — | Stock Award(Grant) at price 3.46 per share. | ABALLI JOHN | Chief Executive Officer | — | 2025-02-28 00:00:00 | D |
| 8 | 15000 | — | — | Stock Award(Grant) at price 0.00 per share. | BLACK JEFFREY G | Chief Financial Officer | — | 2025-02-21 00:00:00 | D |
| 9 | 112500 | — | — | Stock Award(Grant) at price 0.00 per share. | ABALLI JOHN | Chief Executive Officer | — | 2025-02-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -33.04K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.01 | 0.27 |
| NormalizedEBITDA | -11.14M | -19.15M | -38.16M | -23.10M |
| TotalUnusualItems | 0.00 | -5.51M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -5.51M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.12M | -23.69M | -47.39M | -26.85M |
| ReconciledDepreciation | 1.72M | 2.17M | 1.56M | 948.00K |
| ReconciledCostOfRevenue | 22.53M | 23.09M | 24.21M | 20.59M |
| EBITDA | -11.14M | -19.15M | -43.66M | -23.10M |
| EBIT | -12.87M | -21.32M | -45.22M | -24.05M |
| NetInterestIncome | -1.47M | -819.00K | -1.62M | -2.61M |
| InterestExpense | 2.23M | 2.33M | 2.45M | 2.62M |
| InterestIncome | 767.00K | 1.52M | 830.00K | 16.00K |
| NormalizedIncome | -15.12M | -23.69M | -41.91M | -26.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.12M | -23.69M | -47.39M | -26.85M |
| TotalExpenses | 69.28M | 75.39M | 86.11M | 72.37M |
| TotalOperatingIncomeAsReported | -13.64M | -22.84M | -46.05M | -24.07M |
| DilutedAverageShares | 18.20M | 17.68M | 17.08M | 15.97M |
| BasicAverageShares | 18.20M | 17.68M | 17.08M | 15.97M |
| DilutedEPS | -0.83 | -1.34 | -2.77 | -1.68 |
| BasicEPS | -0.83 | -1.34 | -2.77 | -1.68 |
| DilutedNIAvailtoComStockholders | -15.12M | -23.69M | -47.39M | -26.85M |
| NetIncomeCommonStockholders | -15.12M | -23.69M | -47.39M | -26.85M |
| NetIncome | -15.12M | -23.69M | -47.39M | -26.85M |
| NetIncomeIncludingNoncontrollingInterests | -15.12M | -23.69M | -47.39M | -26.85M |
| NetIncomeContinuousOperations | -15.12M | -23.69M | -47.39M | -26.85M |
| TaxProvision | 12.00K | 33.00K | -282.00K | 175.00K |
| PretaxIncome | -15.10M | -23.66M | -47.67M | -26.68M |
| OtherIncomeExpense | -5.51M | 16.00K | ||
| OtherNonOperatingIncomeExpenses | 16.00K | |||
| SpecialIncomeCharges | 0.00 | -5.51M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 5.51M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -1.47M | -819.00K | -1.62M | -2.61M |
| InterestExpenseNonOperating | 2.23M | 2.33M | 2.45M | 2.62M |
| InterestIncomeNonOperating | 767.00K | 1.52M | 830.00K | 16.00K |
| OperatingIncome | -13.64M | -22.84M | -40.55M | -24.07M |
| OperatingExpense | 46.75M | 52.29M | 61.89M | 51.78M |
| ResearchAndDevelopment | 5.38M | 4.87M | 9.88M | 7.24M |
| SellingGeneralAndAdministration | 41.37M | 47.43M | 52.02M | 44.54M |
| GrossProfit | 33.11M | 29.46M | 21.35M | 27.71M |
| CostOfRevenue | 22.53M | 23.09M | 24.21M | 20.59M |
| TotalRevenue | 55.64M | 52.55M | 45.56M | 48.30M |
| OperatingRevenue | 55.64M | 52.55M | 45.56M | 48.30M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 17.64M | 17.05M | 16.55M | 16.16M |
| ShareIssued | 17.64M | 17.05M | 16.55M | 16.16M |
| TotalDebt | 23.00M | 23.23M | 35.20M | 28.07M |
| TangibleBookValue | 9.54M | 22.69M | 42.46M | 79.43M |
| InvestedCapital | 29.79M | 42.19M | 71.43M | 112.41M |
| WorkingCapital | 22.95M | 35.94M | 62.99M | 103.42M |
| NetTangibleAssets | 9.54M | 22.69M | 42.46M | 79.43M |
| CapitalLeaseObligations | 2.76M | 3.74M | 6.23M | 587.00K |
| CommonStockEquity | 9.54M | 22.69M | 42.46M | 84.94M |
| TotalCapitalization | 29.36M | 41.92M | 71.24M | 112.41M |
| TotalEquityGrossMinorityInterest | 9.54M | 22.69M | 42.46M | 84.94M |
| StockholdersEquity | 9.54M | 22.69M | 42.46M | 84.94M |
| RetainedEarnings | -294.33M | -279.22M | -255.53M | -208.14M |
| AdditionalPaidInCapital | 303.85M | 301.89M | 297.97M | 293.06M |
| CapitalStock | 18.00K | 17.00K | 17.00K | 16.00K |
| CommonStock | 18.00K | 17.00K | 17.00K | 16.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 35.15M | 34.25M | 43.76M | 38.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.64M | 22.35M | 34.14M | 29.19M |
| OtherNonCurrentLiabilities | 157.00K | 357.00K | 867.00K | 1.41M |
| NonCurrentDeferredLiabilities | 0.00 | 306.00K | ||
| NonCurrentDeferredTaxesLiabilities | 0.00 | 306.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 21.49M | 21.99M | 33.27M | 27.48M |
| LongTermCapitalLeaseObligation | 1.66M | 2.76M | 4.49M | 0.00 |
| LongTermDebt | 19.82M | 19.23M | 28.78M | 27.48M |
| CurrentLiabilities | 13.51M | 11.90M | 9.62M | 9.32M |
| OtherCurrentLiabilities | 302.00K | 445.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 1.52M | 1.24M | 1.93M | 587.00K |
| CurrentCapitalLeaseObligation | 1.10M | 976.00K | 1.74M | 587.00K |
| CurrentDebt | 423.00K | 264.00K | 190.00K | |
| OtherCurrentBorrowings | 423.00K | 264.00K | 190.00K | |
| PayablesAndAccruedExpenses | 11.99M | 10.66M | 7.25M | 8.73M |
| CurrentAccruedExpenses | 7.85M | 7.53M | 4.20M | 6.24M |
| InterestPayable | 139.00K | 142.00K | 139.00K | |
| Payables | 4.14M | 3.13M | 3.05M | 2.49M |
| AccountsPayable | 4.14M | 3.13M | 3.05M | 2.49M |
| TotalAssets | 44.69M | 56.94M | 86.22M | 123.44M |
| TotalNonCurrentAssets | 8.23M | 9.10M | 13.61M | 10.71M |
| OtherNonCurrentAssets | 550.00K | 616.00K | 528.00K | 433.00K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 5.51M | ||
| Goodwill | 0.00 | 5.51M | ||
| NetPPE | 7.68M | 8.49M | 13.08M | 4.77M |
| AccumulatedDepreciation | -6.01M | -5.77M | -5.12M | -3.88M |
| GrossPPE | 13.70M | 14.26M | 18.21M | 8.66M |
| Leases | 3.29M | 3.32M | 5.22M | 1.15M |
| ConstructionInProgress | 1.54M | 59.00K | 1.38M | 1.85M |
| OtherProperties | 6.65M | 8.60M | 10.02M | 4.36M |
| MachineryFurnitureEquipment | 2.22M | 2.28M | 1.58M | 1.29M |
| BuildingsAndImprovements | 4.88M | 0.00 | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 36.45M | 47.84M | 72.61M | 112.73M |
| OtherCurrentAssets | 859.00K | 1.93M | 236.00K | 490.00K |
| PrepaidAssets | 5.72M | 2.87M | 3.91M | 3.15M |
| Receivables | 7.83M | 6.55M | 6.08M | 9.65M |
| AccountsReceivable | 7.83M | 6.55M | 6.08M | 9.65M |
| AllowanceForDoubtfulAccountsReceivable | -7.80K | -6.60K | ||
| GrossAccountsReceivable | 7.84M | 6.56M | ||
| CashCashEquivalentsAndShortTermInvestments | 22.04M | 36.49M | 62.39M | 99.44M |
| CashAndCashEquivalents | 22.04M | 36.49M | 62.39M | 99.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.79M | -15.29M | -36.46M | -22.64M |
| RepaymentOfDebt | -861.00K | -10.94M | -696.00K | -525.00K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 69.14M | ||
| CapitalExpenditure | -515.00K | -828.00K | -4.32M | -2.37M |
| InterestPaidSupplementalData | 1.72M | 1.74M | 1.73M | 1.81M |
| EndCashPosition | 22.24M | 36.69M | 62.59M | 99.54M |
| BeginningCashPosition | 36.69M | 62.59M | 99.54M | 57.55M |
| ChangesInCash | -14.46M | -25.90M | -36.95M | 41.99M |
| FinancingCashFlow | -663.00K | -10.63M | -489.00K | 64.68M |
| CashFlowFromContinuingFinancingActivities | -663.00K | -10.63M | -489.00K | 64.68M |
| NetOtherFinancingCharges | -239.00K | -4.45M | ||
| ProceedsFromStockOptionExercised | 198.00K | 306.00K | 446.00K | 511.00K |
| NetCommonStockIssuance | 0.00 | 69.14M | ||
| CommonStockIssuance | 0.00 | 69.14M | ||
| NetIssuancePaymentsOfDebt | -861.00K | -10.94M | -696.00K | -525.00K |
| NetLongTermDebtIssuance | -861.00K | -10.94M | -696.00K | -525.00K |
| LongTermDebtPayments | -861.00K | -10.94M | -696.00K | -525.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -515.00K | -804.00K | -4.32M | -2.42M |
| CashFlowFromContinuingInvestingActivities | -515.00K | -804.00K | -4.32M | -2.42M |
| NetOtherInvestingChanges | -50.00K | |||
| NetPPEPurchaseAndSale | -515.00K | -804.00K | -4.32M | -2.37M |
| SaleOfPPE | 0.00 | 24.00K | 0.00 | |
| PurchaseOfPPE | -515.00K | -828.00K | -4.32M | -2.37M |
| OperatingCashFlow | -13.28M | -14.46M | -32.14M | -20.27M |
| CashFlowFromContinuingOperatingActivities | -13.28M | -14.46M | -32.14M | -20.27M |
| ChangeInWorkingCapital | -3.08M | 325.00K | 1.67M | -61.00K |
| ChangeInOtherCurrentLiabilities | -976.00K | -1.01M | -854.00K | 0.00 |
| ChangeInOtherCurrentAssets | 63.00K | -101.00K | -47.00K | -167.00K |
| ChangeInPayablesAndAccruedExpense | 908.00K | 2.56M | -501.00K | 329.00K |
| ChangeInAccruedExpense | 600.00K | 2.50M | -1.40M | 984.00K |
| ChangeInPayable | 308.00K | 67.00K | 901.00K | -655.00K |
| ChangeInAccountPayable | 308.00K | 67.00K | 901.00K | -655.00K |
| ChangeInPrepaidAssets | -1.79M | -654.00K | -505.00K | 521.00K |
| ChangeInReceivables | -1.28M | -474.00K | 3.58M | -744.00K |
| ChangesInAccountReceivables | -1.28M | -474.00K | 3.58M | -744.00K |
| OtherNonCashItems | 1.31M | 2.93M | 1.72M | 819.00K |
| StockBasedCompensation | 1.76M | 3.62M | 4.70M | 4.73M |
| AssetImpairmentCharge | 0.00 | 5.90M | 0.00 | |
| DeferredTax | 0.00 | -306.00K | 148.00K | |
| DeferredIncomeTax | 0.00 | -306.00K | 148.00K | |
| DepreciationAmortizationDepletion | 1.72M | 2.17M | 1.56M | 948.00K |
| DepreciationAndAmortization | 1.72M | 2.17M | 1.56M | 948.00K |
| OperatingGainsLosses | 111.00K | 189.00K | ||
| NetIncomeFromContinuingOperations | -15.12M | -23.69M | -47.39M | -26.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XGN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|